Sigma-Aldrich Corp Quarterly Earnings on Deck

S&P 500 (NYSE:SPY) component Sigma-Aldrich Corp (NASDAQ:SIAL) will unveil its latest earnings on Tuesday, October 25, 2011. Sigma-Aldrich is a life science and high technology company that develops, manufactures, purchases and distributes a range of high quality chemicals, biochemicals and equipment.

Sigma-Aldrich Corp Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 91 cents per share, a rise of 9.6% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. For the year, analysts are projecting profit of $3.70 per share, a rise of 11.8% from last year.

Past Earnings Performance: Last quarter, the company beat estimates by one cent, coming in at net income of 93 cents a share versus the estimate of profit of 92 cents a share. It marked the fourth straight quarter of beating estimates.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: On average, analysts predict $632.3 million in revenue this quarter, a rise of 12.3% from the year ago quarter. Analysts are forecasting total revenue of $2.54 billion for the year, a rise of 11.4% from last year’s revenue of $2.28 billion.

Analyst Ratings: six out of 11 analysts surveyed (54.5%) have a buy rating on Sigma-Aldrich.. This is below the mean analyst rating of 10 competitors, which average 56.3% buy ratings.

A Look Back: In the second quarter, profit rose 16.5% to $113 million (91 cents a share) from $97 million (79 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 15% to $637 million from $554 million.

Key Stats:

The company has seen net income rise in three straight quarters. Net income rose 19% in the first quarter and 1.5% in the fourth quarter of the last fiscal year.

Revenue has risen the past four quarters. Revenue rose 10.5% in the first quarter from the year earlier, climbed 1.7% in the fourth quarter of the last fiscal year from the year-ago quarter and 5.5% in the third quarter of the last fiscal year.

Competitors to Watch: Techne Corporation (NASDAQ:TECH), Life Technologies Corp. (NASDAQ:LIFE), Qiagen NV (NASDAQ:QGEN), Thermo Fisher Scientific Inc. (NYSE:TMO), Affymetrix, Inc. (NASDAQ:AFFX), Hawkins, Inc. (NASDAQ:HWKN), Enzo Biochem, Inc. (NYSE:ENZ), Aceto Corporation (NASDAQ:ACET), Strategic Diagnostics Inc. (NASDAQ:SDIX), and PerkinElmer, Inc. (NYSE:PKI).

Stock Price Performance: During August 23, 2011 to October 19, 2011, the stock price had risen $5.23 (8.7%) from $60.13 to $65.36. The stock price saw one of its best stretches over the last year between April 18, 2011 and April 27, 2011 when shares rose for seven-straight days, rising 8.9% (+$5.76) over that span. It saw one of its worst periods between July 25, 2011 and August 2, 2011 when shares fell for seven-straight days, falling 13.3% (-$9.77) over that span. Shares are down 65 cents (-1%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.